rituximab
英
美
网络 抗体; 利妥昔; 利妥昔单克隆抗体
双语例句
- Efficacy of rituximab in patients with refractory severe systemic lupus erythematosus
利妥昔单抗治疗难治性重症系统性红斑狼疮的临床初步观察 - Objective To investigate the efficacy and safety of combined fludarabine and rituximab therapy for chronic lymphocytic leukemia in old patients.
目的考察氟达拉滨联合治疗高龄慢性淋巴细胞白血病患者的有效性和安全性。 - Toxic epidermal necrolysis has been reported for rituximab, but the relationship of toxic epidermal necrolysis to bendamustine has not been determined.
已报道有关利妥昔单抗的毒性表皮坏死，但毒性表皮坏死和苯达莫司汀的关系尚不确定。 - Clinical observation on rituximab combined with chemotherapy in the treatment of diffused large B cell lymphoma
利妥昔单抗联合化疗治疗弥漫型大B细胞淋巴瘤的临床观察 - Rituximab therapy for rheumatoid arthritis
利妥昔单抗治疗类风湿性关节炎基础研究临床应用现状及展望 - Treatment with immunosuppressants such as rituximab, azathioprine and cyclophosphamide resulted in a marked reduction in antibody levels and relapse rates.
免疫抑制剂治疗，如利妥昔单抗，硫唑嘌呤和环磷酰胺，明显减少抗体水平和复发率。 - It is possible to achieve selective depletion of B lymphocytes with rituximab, an anti-CD20 monoclonal antibody.
用抗CD20的单克隆抗体利妥昔单抗能够做到选择性的消耗B淋巴细胞。 - Patients get rituximab through infusion into a vein ( IV) at the oncologist's office or clinic.
患者可在肿瘤专家的办公室或门诊接受静脉注入美罗华。 - Treatment of B-cell Lymphoma with the Regimen of Rituximab Combined Chemotherapy
利妥昔单抗联合化疗方案治疗B细胞淋巴瘤 - Use of Rituximab in Infant Childhood Immune Thrombocytopenic Purpura Who Useless with Routine Treatment
利妥昔单抗治疗婴幼儿常规治疗无效的特发性血小板减少性紫癜 - Protection of ward of liver cancer patients after undergoing~ ( 131) I rituximab intervention therapy
~（131）碘美妥昔单抗介入治疗肝癌术后病室的防护 - Conclusion The use of rituximab treatment should be closely monitored to ensure the safety of drug use.
结论使用利妥昔单抗治疗应严密监护，保证用药安全。 - Temozolomide United rituximab in the treatment of recurrent Central nervous system lymphoma ( a case report)
替莫唑胺联合美罗华治疗复发中枢神经系统淋巴瘤（附1例报告） - Comparison of Rituximab plus CHOP regimen and CHOP regimen alone for treatment of patients with aggressive B-cell lymphoma
美罗华联合CHOP方案与CHOP方案治疗侵袭性B细胞性淋巴瘤的临床对比研究 - Results At1 year, the mean AUC for the level of C peptide was significantly higher in the rituximab group than in the placebo group.
结果：一年以后，利妥昔单抗组C肽水平的平均曲线下面积明显高于安慰机组。 - Rituximab specifically recognizes and attaches to a protein called CD20 that is found on the surface of some lymphocytes.
美罗华特异的识别和附着于在一些淋巴细胞表面可以找到蛋白CD20。 - CD19+ B lymphocytes were depleted in patients in the rituximab group, but levels increased to69% of baseline values at12 months.
CD19阳性的B淋巴细胞在利妥昔单抗组里被耗尽，但是在低12个月的时候又回复到基线值的69%。 - Moreover, AQP4-Ab titres were found to correlate with CD19 cell counts during therapy with rituximab.
而且，我们发现，在利妥昔单抗治疗期间，水通道蛋白4抗体滴度与CD19细胞数相关。 - The clinical study of CHOP combined with Rituximab in treating B-cell non-Hodgkin lymphoma
美罗华联合CHOP治疗B细胞性非霍奇金淋巴瘤的临床研究 - First biotechnology product approved by FDA to treat patients with cancer-a monoclonal antibody called rituximab, used to treat one type of lymphoma.
FDA批准首个治疗癌症的生物技术药物-一种称为利妥昔的单克隆抗体治疗一种淋巴瘤。 - The rituximab group also had significantly lower levels of glycated hemoglobin and required less insulin.
另外，相对于安慰机组，利妥昔单抗组的糖化血红蛋白和胰岛素必须量都明显较低。 - We examined the significance of bone marrow involvement in patients treated in the current era of therapy including rituximab.
我们的研究旨在探讨骨髓侵犯对接受利妥昔单抗联合化疗的受试者的预后影响。 - Objective To evaluate the efficacy and toxicity of combination of Rituximab and CHOP regimen in diffuse large B-cell lymphoma ( DLBCL).
目的研究利妥昔单抗联合CHOP方案治疗弥漫大B细胞型淋巴瘤的疗效和不良反应。 - There was no increase in infections or neutropenia with rituximab.
感染和中性粒细胞减少症都没有增加。 - Objective To investigate the adverse reactions of rituximab ( Rituxan and MabThera) in retrospection to provide references for safe and rational drug use clinically.
目的探讨抗肿瘤靶向药物利妥昔单抗（美罗华）不良反应的特点及规律，为临床安全、合理用药提供参考。 - Nursing Care for Patients with B-Cell Non-Hodgkin's Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation Combined with Rituximab
2例B细胞非霍奇金淋巴瘤患者异基因造血干细胞移植联合利妥昔单抗治疗的护理 - This is the first study demonstrating a clear benefit of rituximab maintenance following a rituximab-containing induction regimen.
这是首个显示出在进行了包含美罗华的诱导疗法之后采用美罗华维持疗法有明显益处的试验。 - Systematic Review of Maintenance Rituximab Therapy in B Cell Non-Hodgkin Lymphoma
利妥昔单抗维持治疗B细胞非霍奇金淋巴瘤的系统评价 - A Meta-analysis on Rituximab Combined Chemotherapy for Non-hodgkin Lymphoma
美罗华联合化疗对非霍奇金淋巴瘤疗效的Meta分析